GlobeNewsWire
12 Nov 2025, 14:00 UTC · 46w ago
Verdict
Headline takes no side. We score CNTB +0.60 across three claims — strongly bullish.
+0.60strongly bullish
More positive than 76% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
China's NMPA has accepted the New Drug Application (NDA) for rademikibart for the treatment of atopic dermatitis submitted by licensee Simcere.
More positive than 93% of claims this week
The company expects to report topline data from Phase 2 Seabreeze STAT studies for acute asthma and COPD exacerbations in the first half of 2026.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More positive than 78% of claims this week
Connect Biopharma has completed the termination of its ADR program and transitioned to a direct listing of ordinary shares on the Nasdaq.
So whatThis is a structural corporate change that improves accessibility for investors but does not fundamentally change the company's valuation.
More positive than 44% of claims this week
Which stocks this story touches
More positive than 76% of ticker scores this week
The company reported positive clinical data for rademikibart and progress on its New Drug Application in China.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
24/7 Wall Street
14h ago
−39.0%
Price is moving against the score
$0.9270 vs $1.52 close before publication (Nov 11) · not market-adjusted
CNTB chart →
